MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-24-2026
Curis Net Debt 2011-2026 | CRIS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Curis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.44 M | -17 M | -23.9 M | -15.7 M | -35 M | -128 M | -15.3 M | 11.8 M | 3.27 M | -6.18 M | -8.93 M | 20.6 M | 21 M | 47.1 M | -15.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 47.1 M | -128 M | -11 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K |  USA |
 |
BioNTech SE
BNTX
|
-973 M | $ 97.5 | -5.75 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Burford Capital Limited
BUR
|
-135 M | $ 5.12 | 3.75 % | $ 820 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 21.94 | -2.27 % | $ 3.64 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Cerus Corporation
CERS
|
-6.9 M | $ 2.55 | 25.37 % | $ 486 M | USA |
 |
Athira Pharma
ATHA
|
-68.5 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-42.5 M | - | - | $ 3.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
-22.3 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cardiff Oncology
CRDF
|
-16.6 M | $ 1.72 | -0.87 % | $ 115 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-57.6 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-65.3 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | USA |
 |
Editas Medicine
EDIT
|
-87 M | $ 2.91 | -3.17 % | $ 258 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 2.93 | -8.15 % | $ 4.82 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
10.2 M | - | -9.21 % | $ 2.55 M | USA |
 |
Edesa Biotech
EDSA
|
-7.74 M | $ 17.74 | -2.93 % | $ 56.7 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-9.94 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Evogene Ltd.
EVGN
|
-3.44 M | $ 0.79 | 1.67 % | $ 27.9 M | Israel |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | USA |